← Leaderboards
Kevin Xu
Bexion Pharmaceuticals, Inc.
$2,566,138
Attributed
$4,887,004
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $960.3K · FY2007–15$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,887,004 · 4
By mechanism
R44$4,368,595 · 1
R43$518,409 · 3
Top collaborators
- Xiaoyang Qi6 shared
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelSmall Business Innovation Research GrantNeoplastic CellIn VivoBeta-Glucosidase Stimulating ProteinTumorAnimalsMembraneDoseChemotherapyKillingsTumor GrowthSafetyToxic EffectCancer CellNormal CellPre-ClinicalCatabolismDrug KineticsGlioblastomaGrowthMorbidity - Disease RateImplantAffinity
Grant awards (8)
SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme$948,501
R44 · FY2015 · CA · contact PI
SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme$948,501
R44 · FY2014 · CA · contact PI
SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme$960,270
R44 · FY2013 · CA · contact PI
SapC-DOPS nanovesicles for Treating Glioblastoma Multiforme$840,956
R44 · FY2011 · CA · contact PI
SapC-DOPS nanovesicles for Treating Glioblastoma Multiforme$670,367
R44 · FY2010 · CA · contact PI
SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme$273,138
R43 · FY2008 · CA · contact PI
A Novel Biotherapeutic Treatment for Pancreatic Cancer$99,965
R43 · FY2008 · CA · contact PI
A novel biotherapeutic treatment for prostate cancer$145,306
R43 · FY2007 · CA · contact PI